Dr. Fahar Merchant reports

MEDICENNA STRENGTHENS U.S. PATENT ESTATE WITH NEWLY ISSUED AND ALLOWED PATENTS ACROSS ITS IL-2, IL-4 AND IL-13 SUPERKINE PLATFORMS

Medicenna Therapeutics Corp. has been issued two new U.S. patents and allowed an additional U.S. patent application covering its proprietary IL-4 and IL-13 superkine platforms, including bizaxofusp (formerly MDNA55), the company's IL-4 empowered superkine in clinical development for recurrent glioblastoma.

The newly issued U.S. patents, together with parallel patents recently granted in Australia and Canada within the same patent families, further reinforce Medicenna's intellectual property position across the cytokine biology underlying its lead clinical programs: bizaxofusp, MDNA11 (IL-2 superkine) and MDNA113 (anti-PD-1 IL-2 bifunctional superkine).

"These newly issued and allowed U.S. patents underscore the depth and breadth of the superkine science Medicenna has built and the strength of the IP estate now protecting the platforms behind bizaxofusp, MDNA11 and MDNA113," said Dr. Fahar Merchant, president and chief executive officer of Medicenna. "Our cytokine engineering work spans three distinct receptor systems, including IL-2, IL-4 and IL-13, and these grants extend protection into important new applications, including cellular immunotherapy and combination treatment of CNS tumours. With more than 100 active granted patents and applications worldwide, Medicenna has assembled what we believe is one of the most comprehensive patent estates in superkine-based immunotherapy."

U.S. patents recently issued:

• U.S. patent No. 12,503,496: "Interleukin-4 receptor-binding fusion proteins and uses thereof" (Medicenna and the U.S. National Institutes of Health, co-owners); the issued patent covers the application of Medicenna's proprietary IL-4 superkine fusion proteins to enhancing cellular immunotherapy; with this grant, the family now includes three issued U.S. patents and additional granted patents in Europe and India;
• U.S. patent No. 12,590,133: "IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof" (in-licensed by Medicenna from Stanford University); the issued patent is directed to IL-13 superkine immune cell targeting constructs, vectors and engineered cells; the family is granted in the United States and China, with pending applications in Canada and Europe.

U.S. patent recently allowed:

• U.S. patent application No. 18/248,601: "Combination therapy of MDNA55 and a vascular endothelial growth factor A" (Medicenna owned); once issued, the patent will cover combinatorial treatment of CNS tumours with bizaxofusp, including with VEGF-A-directed agents; the family also has pending applications in Canada, China, Europe, India, Japan and Korea.

Additional recent patent grants outside of the United States

In parallel with these U.S. milestones, Medicenna recently received patent grants in two additional jurisdictions that extend the geographic reach of its core superkine families:

• Australian patent No. 2018347796, "IL-4 fusion formulations for treatment of central nervous system tumors," directed to Medicenna's proprietary bizaxofusp formulation and its application to the treatment of CNS tumours; this family is granted in Australia, Europe and the United States, with pending applications in Canada, China and India;
• Canadian patent No. 3,067,909, "uses and methods for IL-2 superagonists, agonists and fusions thereof," directed to the combination of Medicenna's IL-2 superagonist and checkpoint inhibitors for the treatment of cancer; this family is granted in Australia, Canada, Japan and the United States, with additional pending applications in China, Europe and India, as well as further applications in Australia, Japan and the United States.

Medicenna continues to develop a robust global patent portfolio across its research and development platforms and clinical programs, with over 100 active granted patents and applications.

About Medicenna Therapeutics Corp.

Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 superkines and first-in-class empowered superkines. Medicenna's long-acting IL-2 superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T-cells and NK-cells. Medicenna's first-in-class targeted PD-1 IL-2 bispecific, MDNA113, is in development for solid tumours and was designed using the company's proprietary BiSKITs (bifunctional superkine immunotherapies) and T-MASK (targeted metalloprotease activated superkine) platforms. Medicenna's IL-4 empowered superkine, bizaxofusp (formerly MDNA55), has been studied in five clinical trials enrolling over 130 patients, including a phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained fast-track and orphan drug status from the Food and Drug Administration and FDA/European Medicines Agency, respectively.

We seek Safe Harbor.